Literature DB >> 33275704

How do we sequence therapy for marginal zone lymphomas?

Alessandro Broccoli1, Pier Luigi Zinzani1.   

Abstract

Marginal zone lymphomas are indolent diseases. Overall survival rates are very good, but patients tend to relapse and may do so several times. The concept of treatment sequencing is therefore important and necessary to preserve adequate organ function and to avoid excessive toxicity, with the final goal of achieving long survival times. Systemic treatments and chemotherapy are considered to be an option in multiply relapsing disease, in cases that are in an advanced stage at presentation or relapse, and in cases where initial local treatments lack efficacy. Targeted agents and new drugs can provide chemotherapy-free alternatives in heavily pretreated patients.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33275704      PMCID: PMC7727586          DOI: 10.1182/hematology.2020000157

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  62 in total

Review 1.  Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.

Authors:  Barbara Kiesewetter; Andrés J M Ferreri; Markus Raderer
Journal:  Oncologist       Date:  2015-07-08

2.  Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Authors:  Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

3.  Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Authors:  Antonio Salar; Eva Domingo-Domenech; Carlos Panizo; Concepción Nicolás; Joan Bargay; Ana Muntañola; Miguel Canales; José Luis Bello; Juan Manuel Sancho; José Francisco Tomás; María José Rodríguez; Javier Peñalver; Carlos Grande; José Javier Sánchez-Blanco; Luis Palomera; Reyes Arranz; Eulogio Conde; Mar García; Juan Fernando García; Dolores Caballero; Carlos Montalbán
Journal:  Blood       Date:  2017-08-11       Impact factor: 22.113

Review 4.  Possible novel agents in marginal zone lymphoma.

Authors:  Pier Luigi Zinzani; Alessandro Broccoli
Journal:  Best Pract Res Clin Haematol       Date:  2016-11-04       Impact factor: 3.020

5.  Rituximab monotherapy for splenic marginal zone lymphoma.

Authors:  Michael Bennett; Kumud Sharma; Shaiy Yegena; Israel Gavish; Harish P Dave; Geraldine P Schechter
Journal:  Haematologica       Date:  2005-06       Impact factor: 9.941

Review 6.  The many faces of marginal zone lymphoma.

Authors:  Pier Luigi Zinzani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy.

Authors:  Jayant S Goda; Mary Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Micheal Crump; Richard W Tsang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

8.  A MALT lymphoma prognostic index.

Authors:  Catherine Thieblemont; Luciano Cascione; Annarita Conconi; Barbara Kiesewetter; Markus Raderer; Gianluca Gaidano; Maurizio Martelli; Daniele Laszlo; Bertrand Coiffier; Armando Lopez Guillermo; Valter Torri; Franco Cavalli; Peter W Johnson; Emanuele Zucca
Journal:  Blood       Date:  2017-07-18       Impact factor: 22.113

9.  First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Authors:  Antonio Salar; Eva Domingo-Domenech; Carlos Panizo; Concepción Nicolás; Joan Bargay; Ana Muntañola; Miguel Canales; José Luis Bello; Juan Manuel Sancho; José Francisco Tomás; María José Rodríguez; Francisco Javier Peñalver; Carlos Grande; José Javier Sánchez-Blanco; Luis Palomera; Reyes Arranz; Eulogio Conde; Mar García; Juan Fernando García; Dolores Caballero; Carlos Montalbán
Journal:  Lancet Haematol       Date:  2014-11-19       Impact factor: 18.959

10.  Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.

Authors:  J Valencak; F Weihsengruber; K Rappersberger; F Trautinger; A Chott; B Streubel; L Muellauer; M Der-Petrossian; C Jonak; M Binder; M Raderer
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

View more
  3 in total

Review 1.  Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.

Authors:  Thomas E Lew; John F Seymour
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

Review 2.  Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Chung-Wu Lin; Jyh-Ming Liou; Ming-Shiang Wu; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

3.  Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study.

Authors:  Sung-Yong Kim; Won-Sik Lee; Sung Yong Oh; Deok-Hwan Yang; Hyo Jung Kim; Seong Kyu Park; Jae Wook Yang; Suk-Woo Yang; Seok-Goo Cho
Journal:  Cancer Med       Date:  2022-03-11       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.